The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  International Immunopharmacology

• Publication date

  2004-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.INTIMP.2004.07.009PMID 15351320
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment for lupus nephritis.

  2004cited by this paper
• Comparative methodologic study of NFκB activation in cultured endothelial cells

  2000cited by this paper
• Comparative methodologic study of NFkappaB activation in cultured endothelial cells.

  2000cited by this paper
• Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis.

  1997cited by this paper
• Murine models for systemic lupus erythematosus

  1996cited by this paper
• Neutrophil mediated inflammatory response in murine lupus.

  1993cited by this paper
• The effect of immunomodulating treatment on cutaneous delayed‐type hypersensitivity in MRL lpr/lpr mice

  1989cited by this paper
• Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice.

  1986cited by this paper
• Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma.

  1986cited by this paper
• Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator.

  1986cited by this paper
• Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat.

  1986cited by this paper
• Murine models of systemic lupus erythematosus.

  1985cited by this paper
• Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator.

  1985cited by this paper
• Cyclophosphamide-induced changes in the MRL-lpr/lpr mouse: effects upon cellular composition, immune function, and disease.

  1984cited by this paper
• The usability of the MRL/1 mouse strain in detection of anti-rheumatic drugs

  1984cited by this paper
• A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells.

  1983cited by this paper
• Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains

  1978cited by this paper

• DSS-induced inflammation in the colon drives a proinflammatory signature in the brain that is ameliorated by prophylactic treatment with the S100A9 inhibitor paquinimod

  2021cites this paper
• DSS-induced inflammation in the colon drives a proinflammatory signature in the brain that is ameliorated by prophylactic treatment with the S100A9 inhibitor paquinimod

  2021cites this paper
• Discerning the promising binding sites of S100/calgranulins and their therapeutic potential in atherosclerosis

  2021cites this paper
• Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs

  2020cites this paper
• S100A12 and the S100/CalgranulinsSignificance

  2015cites this paper
• S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets.

  2015cites this paper
• Small molecules in the treatment of systemic lupus erythematosus.

  2013cites this paper
• Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice.

  2013influential citation
• Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.

  2012cites this paper